Boehringer Ingelheim begins phase IIa trial of BI 765423, a novel monoclonal antibody targeting IL-11, in patients with idiopathic pulmonary fibrosis: Ingelheim, Germany Thursday, ...
Boehringer Ingelheim advances IL-11 ... • BI 765423 has been developed to target IL-11, a key driver of fibrosis • The potential first-in-class inhibitor is an acquired asset from Enleofen with ...
Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will ...
Booster Therapeutics (Germany) focuses on developing small-molecule proteasome activators for neurodegenerative disease using ...
A new study published in the Journal of the European Academy of Dermatology & Venerology showed that in children with severe ...
A recent study published in the journal Breast Cancer Research has found that adolescent girls who engage in regular organised physical activity show favourable changes in breast tissue composition ...
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...
A new study maps how prenatal stress alters immune signalling in the developing brain at a level of detail not seen before ...
New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia ...
Q: A lot of my friends are doing Dry January but I don’t drink enough to bother with it. Still, I like the idea of giving up ...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B ...
Nonetheless, the authors concluded, “Liver biopsy is considered the gold standard for diagnosing MASH and MASLD. While ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback